ADVA
9.7.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that KCOM has deployed its packet edge technology to support the extended rollout of super-fast full fiber broadband. Using the compact ADVA FSP 150 demarcation and aggregation device, the UK-based communication and IT service provider is delivering its gigabit-speed Lightstream services to tens of thousands more business and residential customers in the Yorkshire and Lincolnshire area. The high-density MEF 3.0-certified technology enables KCOM to smoothly transition from 1Gbit/s to 10Gbit/s services in its access network. ADVA’s packet edge solution also ensures that the new infrastructure is ready for 5G mobile services and can easily scale to 200Gbit/s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005034/en/
“Our Lightstream service has already had a huge impact on businesses and in homes across this region. Now, ADVA’s technology is empowering us to go further than ever before by creating the UK’s first full-fiber city and delivering super-fast fiber connectivity to previously underserved areas,” said Tim Shaw, managing director, wholesale and networks, KCOM. “By leveraging ADVA’s packet edge device, we’ve been able to smoothly transition to 100Gbit/s capacity in our access network and aggregate lower-speed services. What makes the solution so valuable though are its extra benefits. As well as a small footprint and low power, ADVA’s packet edge technology comes with fully automated service activation. Together with its extended temperature range, this makes it simple to deploy in any environment and on a large scale.”
KCOM’s new network is built on ADVA's 100Gbit/s FSP 150 solution with MEF 3.0 Carrier Ethernet certification. The technology supports 100Gbit/s demarcation and high-scale 10Gbit/s service aggregation in an incredibly compact form factor. KCOM is managing the infrastructure with ADVA’s Ensemble Controller , a unique management system that enables programmatic SDN control. This further improves efficiency by reducing troublesome and time-consuming manual processes while providing KCOM’s maintenance team with total visibility. With its hardware-based timing and full activation testing, the solution also helps KCOM ensure the highest levels of quality and availability. What’s more, its low power consumption and ultra-compact design are key to keeping the cost of KCOM’s Lightstream services low.
“We’re proud to be supporting KCOM in this next phase of its journey. By harnessing our technology and the expertise of our team, KCOM is providing high-speed connectivity to more properties than ever before. It’s also helping to boost the economy in this region of the UK by empowering businesses to expand and seize new revenue opportunities,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our FSP 150 packet edge device features several unique advantages, such as its unique ability to verify the performance of high-bitrate services with line-rate 100Gbit/s pre-activation testing. It really is the ultimate tool for operators who need to scale their networks quickly and affordably to tackle exponential growth in data demand and lay the foundations for 5G.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About KCOM
KCOM is a leading provider of communications and IT services. Its foundations date back to 1904 when Hull’s local authority established its own telephone network and it is the reason Hull is the only city in the UK where BT does not operate. KCOM was owned entirely by Hull City Council until its flotation on the London Stock Exchange in 1999 and in August 2019 it was acquired for £627m by Macquarie European Infrastructure Fund 6, an investment fund managed by Macquarie Infrastructure and Real Assets (MIRA). The company has a long history of innovation. It installed the first all-digital telephone network in Europe and launched the first commercial broadband service in the UK. It also introduced the UK’s first online TV service in 1999, pre-empting today’s streaming and downloading technology by decades. Today KCOM provides broadband and phone services to more than 140,000 consumers and businesses in Hull and East Yorkshire while its national arm provides connectivity and IT services to public and private sector organisations across the UK. www.kcom.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005034/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
